Dornase alfa

Dornase alfa is a clinically significant recombinant human deoxyribonuclease I (rhDNAse) that possesses selective DNA cleaving activity. When administered into the pleural cavity, it effectively catalyzes the degradation of extracellular DNA in airway secretions, leading to a reduction in their viscosity. This facilitates the clearing of mucus from the airways and potentially enhances overall pulmonary function.

Overview

Dornase alfa is a prime example of how biotechnological advancements can be applied in therapeutic settings. Its mechanism of action targets the thick mucus often seen in certain respiratory conditions by breaking down extracellular DNA, a primary contributor to mucus viscosity.

Mechanism of Action

Upon intrapleural administration, dornase alfa specifically targets and cleaves extracellular DNA strands present in the airway secretions. As DNA contributes to the thick and sticky nature of the mucus, its degradation by dornase alfa results in a more fluid and less viscous mucus, facilitating its clearance from the respiratory tract.

Therapeutic Benefits

• Mucus Clearance: By reducing the viscosity of airway secretions, dornase alfa promotes more efficient mucus clearance.
• Improved Pulmonary Function: Regular clearing of the airways may lead to improved lung function over time.
• Reduced Respiratory Complications: The effective management of mucus can lead to fewer pulmonary complications, such as infections and airway obstructions.

Clinical Uses

Dornase alfa is primarily utilized in the management of patients with conditions characterized by thickened mucus secretions in the airways, particularly in diseases like Cystic Fibrosis. By improving mucus clearance, the therapy can lead to better respiratory outcomes and overall quality of life for patients.

Side Effects and Precautions

As with any therapeutic agent, dornase alfa may have potential side effects. It's essential for patients to be monitored regularly and to report any unusual symptoms to their healthcare provider.

Research and Development

The development of dornase alfa represents the intersection of molecular biology and clinical therapeutics. Its creation was made possible through advanced recombinant DNA techniques.

See Also

• Recombinant DNA
• Cystic Fibrosis
• Pulmonary Medicine

• Dailymed label info on Dornase alfa
• FDA Dornase alfa

Dornase alfa Resources
Latest articles Most recent articles Ongoing trials	Wikipedia